CA3122996A1 - Novel thyromimetics - Google Patents

Novel thyromimetics Download PDF

Info

Publication number
CA3122996A1
CA3122996A1 CA3122996A CA3122996A CA3122996A1 CA 3122996 A1 CA3122996 A1 CA 3122996A1 CA 3122996 A CA3122996 A CA 3122996A CA 3122996 A CA3122996 A CA 3122996A CA 3122996 A1 CA3122996 A1 CA 3122996A1
Authority
CA
Canada
Prior art keywords
compound
disease
pharmaceutically acceptable
salt
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3122996A
Other languages
English (en)
French (fr)
Inventor
Bradley BACKES
Thomas Von Geldern
Jean-Christophe Poupon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autobahn Therapeutics Inc
Original Assignee
Autobahn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/120634 external-priority patent/WO2020118564A1/en
Application filed by Autobahn Therapeutics Inc filed Critical Autobahn Therapeutics Inc
Publication of CA3122996A1 publication Critical patent/CA3122996A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12Acetic acid esters
    • C07C69/14Acetic acid esters of monohydroxylic compounds
    • C07C69/145Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
    • C07C69/157Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/34Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings containing more than one carboxyl group
    • C07C57/36Phenymalonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • C07C69/736Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3122996A 2018-12-12 2019-12-12 Novel thyromimetics Pending CA3122996A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/120634 2018-12-12
PCT/CN2018/120634 WO2020118564A1 (en) 2018-12-12 2018-12-12 Novel thyromimetics
US201962907455P 2019-09-27 2019-09-27
US62/907,455 2019-09-27
PCT/US2019/066066 WO2020123861A1 (en) 2018-12-12 2019-12-12 Novel thyromimetics

Publications (1)

Publication Number Publication Date
CA3122996A1 true CA3122996A1 (en) 2020-06-18

Family

ID=69160374

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3122996A Pending CA3122996A1 (en) 2018-12-12 2019-12-12 Novel thyromimetics

Country Status (7)

Country Link
US (1) US11827596B2 (https=)
EP (1) EP3894383A1 (https=)
JP (1) JP2022513449A (https=)
CN (1) CN113423684A (https=)
AU (1) AU2019397067A1 (https=)
CA (1) CA3122996A1 (https=)
WO (1) WO2020123861A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
KR20220121239A (ko) 2019-11-29 2022-08-31 아우토반 쎄라퓨틱스, 인크. 신규한 갑상선 호르몬 모방제
WO2021247847A1 (en) * 2020-06-03 2021-12-09 Autobahn Therapeutics, Inc. Isotopic thyromimetic compounds
JP7813730B2 (ja) 2020-06-17 2026-02-13 オートバーン セラピューティクス,インク. 甲状腺様作用剤
WO2021257851A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
CN112759515B (zh) * 2020-12-28 2023-06-13 广东药科大学 一种新型FFA1和PPARα/γ/δ四重激动剂、其制备方法及其作为药物的用途
JP2024516852A (ja) * 2021-05-06 2024-04-17 オートバーン セラピューティクス,インク. 甲状腺ホルモン模倣薬の、脂肪酸アミド加水分解酵素(faah)により切断可能なプロドラッグ、および末梢制限faah阻害剤との組合せ

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4723027A (en) 1982-11-22 1988-02-02 E. I. Du Pont De Nemours And Company Preparation of optically active alpha-hydroxynitriles
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4741897A (en) 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
DE10199033I2 (de) 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
DE4320444A1 (de) 1993-06-21 1994-12-22 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
AU717743B2 (en) 1995-12-13 2000-03-30 Regents Of The University Of California, The Nuclear receptor ligands and ligand binding domains
JPH09301917A (ja) * 1996-05-08 1997-11-25 Koichi Shudo 甲状腺ホルモン作用性化合物
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
DE69924846T2 (de) 1998-06-30 2006-04-27 The Regents Of The University Of California, Oakland Thyroidhormon-analoga und verfahren zu ihrer herstellung
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
JP2003500483A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ビアリール化合物
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
CZ20022771A3 (cs) * 2000-02-17 2003-09-17 Bristol-Myers Squibb Company Ligandy thyreoidního receptoru odvozené od anilinu
DE10024939A1 (de) * 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
EP1337524A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB Substituted quinolines as antitumor agents
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US20040267015A1 (en) 2001-04-05 2004-12-30 Ajita Bhat Peptide deformylase inhibitors
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7247748B2 (en) 2002-03-27 2007-07-24 Smithkline Corporation Amide compounds and methods of using the same
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
JP2008513461A (ja) 2004-09-15 2008-05-01 オードウェイ リサーチ インスティテュート 血管形成を促進する甲状腺ホルモンアナログ
AU2006249347A1 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CN101180097A (zh) 2005-05-26 2008-05-14 症变治疗公司 新型含次膦酸的拟甲状腺素药
WO2006128056A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
GB0608724D0 (en) 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
WO2008052354A1 (en) 2006-11-03 2008-05-08 University Of Saskatchewan Method of treating demyelination diseases
CN101547898B (zh) 2006-12-10 2014-09-24 于崇曦 β-内酰胺类抗生素的透皮给药系统
CN101657193A (zh) 2007-03-09 2010-02-24 切尔西治疗公司 用于治疗纤维肌痛的屈昔多巴及其药物组合物
FI20075245A0 (fi) 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CA2970273C (en) 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
EP2242745A1 (de) 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8475804B2 (en) 2009-02-20 2013-07-02 U.S. Army Medical Research And Material Command Compositions and methods for treatment of filovirus-mediated diseases
US20120245213A1 (en) 2009-10-01 2012-09-27 Bedrich Mosinger Human type i taste receptor subunit 3 modulators and methods of using same
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
WO2013006734A1 (en) 2011-07-05 2013-01-10 St. Jude Children's Research Hospital Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
WO2013056232A2 (en) 2011-10-13 2013-04-18 Case Western Reserve University Rxr agonists compounds and methods
WO2014078892A1 (en) 2012-11-21 2014-05-30 Indyk Daniel A device and a test assembly for testing the integrity of a low voltage electrical network
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
WO2015013187A1 (en) 2013-07-22 2015-01-29 Metabolic Solutions Development Co., Llc Ppar-sparing compounds for the treatment of metabolic diseases
US10258613B2 (en) 2014-02-05 2019-04-16 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
US20170114019A1 (en) 2014-06-04 2017-04-27 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
EP3259246B1 (en) 2015-02-20 2023-03-22 Oregon Health & Science University Derivatives of sobetirome
US10532983B2 (en) 2015-07-20 2020-01-14 Oregon Health & Science University Quinolone-3-diarylethers
CN109475121B (zh) 2016-05-18 2021-06-25 俄勒冈健康科学大学 苏比替罗衍生物
US11325886B2 (en) 2016-08-12 2022-05-10 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018208707A1 (en) 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
IL276592B2 (en) 2018-02-14 2023-11-01 Univ Oregon Health & Science History of Subtirum
WO2019168842A1 (en) 2018-03-02 2019-09-06 Oregon Health & Science University Amide prodrugs of small molecule nuclear receptor modulators
WO2020118564A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
KR20220121239A (ko) 2019-11-29 2022-08-31 아우토반 쎄라퓨틱스, 인크. 신규한 갑상선 호르몬 모방제

Also Published As

Publication number Publication date
US11827596B2 (en) 2023-11-28
CN113423684A (zh) 2021-09-21
EP3894383A1 (en) 2021-10-20
WO2020123861A1 (en) 2020-06-18
US20200361849A1 (en) 2020-11-19
JP2022513449A (ja) 2022-02-08
AU2019397067A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
US11827596B2 (en) Thyromimetics
US12466781B2 (en) Thyromimetics
WO2020118564A1 (en) Novel thyromimetics
US12590072B2 (en) Thyromimetics
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
JP7503560B2 (ja) 新規な甲状腺模倣物
US12528761B2 (en) Thyromimetics
KR20140101869A (ko) 베툴린의 프로페노에이트 유도체
CN116514902A (zh) 氘代拟肽类化合物及其用途
WO2021257834A1 (en) Thyromimetics
EA048616B1 (ru) Новые тиромиметики
HK40082050A (zh) 新型拟甲状腺素药
CN108026140A (zh) 用于预防或治疗hiv感染的白桦脂醇衍生物
CN108026139A (zh) 用于预防或治疗hiv感染的白桦脂醇衍生物